Skip to main content

Drug Interactions between brimonidine / dorzolamide / latanoprost / timolol ophthalmic and dasiglucagon

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

timolol ophthalmic brimonidine ophthalmic

Applies to: brimonidine / dorzolamide / latanoprost / timolol ophthalmic and brimonidine / dorzolamide / latanoprost / timolol ophthalmic

MONITOR: Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia. The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.

MANAGEMENT: Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs. Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.

References (7)
  1. King MH, Richards DW (1990) "Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy." Am J Ophthalmol, 110, p. 308-9
  2. "Product Information. Iopidine (apraclonidine ophthalmic)." Alcon Laboratories Inc
  3. Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J (1995) "The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine." Arch Ophthalmol, 113, p. 77-83
  4. (2001) "Product Information. Alphagan (brimonidine ophthalmic)." Allergan Inc
  5. Walters TR (1996) "Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies." Surv Ophthalmol, 41 ( Suppl, s19-26
  6. Pekdemir M, Yanturali S, Karakus G (2005) "More than just an ocular solution." Emerg Med J, 22, p. 753-4
  7. (2013) "Product Information. Mirvaso (brimonidine topical)." Galderma Laboratories Inc
Minor

timolol ophthalmic dasiglucagon

Applies to: brimonidine / dorzolamide / latanoprost / timolol ophthalmic and dasiglucagon

Beta-blockers may blunt the hyperglycemic reaction to glucagon by interfering with beta-adrenergic-mediated hyperglycemic counter-regulatory mechanisms. In addition, glucagon may diminish the bradycardic effect of beta-blockers by inducing a transient increase in pulse and blood pressure. Patients with coronary artery disease may require treatment for the potential increase in blood pressure and heart rate.

References (11)
  1. Pun KK, Yeung CK, Chak W, et al. (1986) "Effects of selective and non-selective beta-blockers on the alanine and free fatty acid responses to glucagon challenge in hemodialysis patients." Clin Nephrol, 26, p. 222-6
  2. Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J (1976) "Effects of B-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol, 14, p. 189-94
  3. Smith RC, Wilkinson DO, Hull RL (1985) "Glucagon for propranolol overdose." JAMA, 254, p. 2412
  4. Mills GA, Horn JR (1985) "B-blockers and glucose control." Drug Intell Clin Pharm, 19, p. 246-51
  5. Smith RC, Wilkinson J, Hull RL (1985) "Glucagon for propranolol overdose." JAMA, 254, p. 2412
  6. (2001) "Product Information. Glucagon (glucagon)." Lilly, Eli and Company
  7. (2001) "Product Information. GlucaGen (glucagon)." Novo Nordisk Pharmaceuticals Inc
  8. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  9. Cerner Multum, Inc. "Australian Product Information."
  10. (2019) "Product Information. Baqsimi (glucagon)." Lilly, Eli and Company
  11. (2021) "Product Information. Zegalogue Prefilled Syringe (dasiglucagon)." Zealand Pharma A/S

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer